| Nov 15 |
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
|
| Nov 15 |
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
|
| Nov 14 |
Arbutus to Present at Jefferies London Healthcare Conference
|
| Nov 7 |
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...
|
| Nov 7 |
Q3 2024 Arbutus Biopharma Corp Earnings Call
|
| Nov 6 |
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 6 |
Arbutus: Q3 Earnings Snapshot
|
| Nov 6 |
Arbutus Biopharma GAAP EPS of -$0.10 misses by $0.01, revenue of $1.34M misses by $0.53M
|
| Nov 6 |
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
